awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
1
Q50047295-E16DDC1B-25B7-4ED0-AB94-A27B2D5DE0E3
Q50047295-E16DDC1B-25B7-4ED0-AB94-A27B2D5DE0E3
BestRank
Statement
http://www.wikidata.org/entity/statement/Q50047295-E16DDC1B-25B7-4ED0-AB94-A27B2D5DE0E3
Alirocumab versus usual lipid-lowering care as add-on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DM-DYSLIPIDEMIA randomized trial.
P2860
Q50047295-E16DDC1B-25B7-4ED0-AB94-A27B2D5DE0E3
BestRank
Statement
http://www.wikidata.org/entity/statement/Q50047295-E16DDC1B-25B7-4ED0-AB94-A27B2D5DE0E3
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
e761402bd570f3174e4651db364b292adb7d0a31
P2860
No effect of PCSK9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY Phase 3 studies.